While GLP-1/GIP dual-agonists have advanced to phase 3 clinical trials for treating obesity and diabetes, the contribution of GIPR agonism to these applications is questionable. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.